ComprehensiveOffering Provides Flexible Access to Key Quality Processes
Sparta Systems, Inc., an industry pioneer and global leader in enterprise quality management software (EQMS) solutions, today announced the availability of a comprehensive mobile solution product suite designed to improve the operational efficiency and effectiveness of its customers’ increasingly mobile workforce. Organizations are now able to significantly expand the reach of their quality processes, reporting and analytics beyond the four walls of their businesses.
Sparta Systems’ mobile product suite includes:
These Sparta Systems’ mobile offerings provide the following business and usability benefits:
“The launch of Sparta System’s mobile product suite underscores our continued commitment and investment in our customers,” said Eileen Martinson, Chief Executive Officer. “The entirely reinvented mobile user experience, combined with delivery as a turnkey service will rapidly accelerate customers’ time to adoption and realization of value.”
TrackWise Mobile product suite has been optimized to work on most Apple iOS devices, with support for Android devices expected later this quarter. To learn more view the TrackWise Mobile video or visit www.spartasystems.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.